Latest News

First Checkpoint Inhibitor for Previously Treated Patients with SCLC Approved by FDA
With this approval, nivolumab (Opdivo) offers a new treatment option for patients with small cell lung cancer whose cancer has progressed after 2 or more prior lines of therapy.
Two new studies highlight trends in life expectancy and mortality across high-income countries, citing worsening health in the United States.
Assessment of neurofilament light chain levels offers real-time, efficient measure marker of multiple sclerosis progression.
States that chose to expand Medicaid eligibility under the Affordable Care Act (ACA) have seen a greater decrease in uninsured rates among low-income patients.
Top news of the week from Specialty Pharmacy Times.
A look at last week's top stories in the world of pharmacy.
The FDA has approved the first generic epinephrine auto-injector for the emergency treatment of allergic reactions, including anaphylaxis.


A Case for Biosimilar Use: 5 Things You Need to Know
Biosimilars are a potential solution to the ever-growing problem of high specialty drug costs.
Specialty infusion pharmacy should be thought of in terms of superlatives, such as most complex and highest cost.
Approximately 80% of manufacturers are already managing their products, many of which are oncology drugs, through a limited distribution model.
The meteoric rise in drug spending over the past 10 years has been driven by specialty therapeutics, while spending on traditional therapies has decreased.

Featured Company Profile

MHA Specialty Pharmacy Solutions: Patient Engagement Strategies for Your Pharmacy


A look at last week's top stories in the world of pharmacy.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, speaks about the regulation of pharmacy benefit managers and how it can impact specialty pharmacy operations.

In this clip, Patricia Kienle, BSPharm, MPA, FASHP, Director of Accreditation and Medication Safety at Cardinal Health Innovative Delivery Solutions, discusses key steps for performing an assessment of risk in compliance with USP 800.

Current Issue

Volume: 9
Number: 5

Most Popular

Previous TabNext Tab
Strategic Alliance Partners
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.